Mathurin Fuméry

9.1k total citations · 2 hit papers
198 papers, 3.3k citations indexed

About

Mathurin Fuméry is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Mathurin Fuméry has authored 198 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Genetics, 111 papers in Epidemiology and 93 papers in Surgery. Recurrent topics in Mathurin Fuméry's work include Inflammatory Bowel Disease (138 papers), Microscopic Colitis (91 papers) and Eosinophilic Esophagitis (27 papers). Mathurin Fuméry is often cited by papers focused on Inflammatory Bowel Disease (138 papers), Microscopic Colitis (91 papers) and Eosinophilic Esophagitis (27 papers). Mathurin Fuméry collaborates with scholars based in France, United States and Belgium. Mathurin Fuméry's co-authors include William J. Sandborn, Siddharth Singh, M. Hassan Murad, Parambir S. Dulai, Laurent Peyrin‐Biroulet, Corinne Gower‐Rousseau, Luc Dauchet, Jean–Frédéric Colombel, Jean‐Louis Dupas and Guillaume Savoye and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Mathurin Fuméry

173 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis

2020 232 citations Siddharth Singh, M. Hassan Murad et al. Clinical Gastroenterology and Hepatology profile →
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis

2021 174 citations Siddharth Singh, M. Hassan Murad et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mathurin Fuméry France	29	2.2k	1.7k	1.0k	788	328	198	3.3k
Marcus Harbord United Kingdom	15	2.2k 1.0×	1.6k 0.9×	843 0.8×	637 0.8×	392 1.2×	26	3.0k
J F Colombel United States	29	2.2k 1.0×	1.7k 1.0×	1.4k 1.3×	797 1.0×	389 1.2×	148	3.6k
Ian C. Lawrance Australia	27	2.0k 0.9×	1.4k 0.8×	783 0.8×	643 0.8×	303 0.9×	85	2.9k
Mark T. Osterman United States	31	2.1k 1.0×	1.7k 1.0×	781 0.8×	707 0.9×	166 0.5×	157	3.2k
Henit Yanai Israel	28	1.8k 0.8×	1.3k 0.8×	923 0.9×	600 0.8×	243 0.7×	125	2.6k
Alfredo Papa Italy	36	1.9k 0.9×	1.4k 0.8×	1.4k 1.4×	673 0.9×	493 1.5×	161	3.9k
Jeffry Katz United States	25	1.4k 0.6×	935 0.6×	787 0.8×	778 1.0×	329 1.0×	88	2.6k
Sang Hyoung Park South Korea	37	2.5k 1.1×	2.0k 1.2×	1.7k 1.7×	639 0.8×	409 1.2×	252	4.5k
Gottfried Novacek Austria	26	1.8k 0.8×	1.6k 1.0×	1.2k 1.2×	387 0.5×	418 1.3×	103	3.3k
Guillaume Bouguen France	30	1.8k 0.8×	1.3k 0.8×	1.3k 1.3×	288 0.4×	187 0.6×	144	2.8k

Countries citing papers authored by Mathurin Fuméry

Since Specialization

Citations

This map shows the geographic impact of Mathurin Fuméry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathurin Fuméry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathurin Fuméry more than expected).

Fields of papers citing papers by Mathurin Fuméry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathurin Fuméry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathurin Fuméry. The network helps show where Mathurin Fuméry may publish in the future.

Co-authorship network of co-authors of Mathurin Fuméry

This figure shows the co-authorship network connecting the top 25 collaborators of Mathurin Fuméry. A scholar is included among the top collaborators of Mathurin Fuméry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathurin Fuméry. Mathurin Fuméry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fuméry, Mathurin, et al.. (2025). Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn’s disease. Therapeutic Advances in Gastroenterology. 18. 1128509447–1128509447.

Laharie, David, Lucine Vuitton, Arnaud Bourreille, et al.. (2024). The Groupe d’Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel Disease. Journal of Crohn s and Colitis. 19(2). 2 indexed citations

Leroyer, Ariane, Hélène Sarter, Claire Dupont, et al.. (2024). P1122 Comorbidities Associated with Pediatric Onset Inflammatory Bowel Diseases: A Population-Based Study. Journal of Crohn s and Colitis. 18(Supplement_1). i2000–i2000.

Yzet, Clara, et al.. (2024). P360 Prevalence and risk factors for fatigue in patients with inflammatory bowel disease and endoscopic healing. Journal of Crohn s and Colitis. 18(Supplement_1). i757–i757. 1 indexed citations

Reenaers, Cathérine, Maria Nachury, David Laharie, et al.. (2024). DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort. Journal of Crohn s and Colitis. 18(Supplement_1). i117–i117. 1 indexed citations

Estevinho, María Manuela, Vishal Midya, Shirley Cohen‐Mekelburg, et al.. (2024). Emerging role of environmental pollutants in inflammatory bowel disease risk, outcomes and underlying mechanisms. Gut. 74(3). 477–486. 18 indexed citations

Petit, Pascal, et al.. (2024). Farming Activities and Risk of Inflammatory Bowel Disease: A French Nationwide Population-based Cohort Study. Journal of Crohn s and Colitis. 18(9). 1415–1429. 5 indexed citations

Reenaers, Cathérine, Maria Nachury, David Laharie, et al.. (2024). Impact of Histological Remission for Predicting Clinical Relapse in Crohn’s Disease: A Post Hoc Analysis of the Prospective STORI Cohort. Journal of Crohn s and Colitis. 19(4). 1 indexed citations

Yzet, Clara, et al.. (2023). P338 Transmural healing is not associated with less disability than complete endoscopic mucosal healing: a prospective study in a patient with Crohn's disease. Journal of Crohn s and Colitis. 17(Supplement_1). i475–i476.

10.

Buisson, Anthony, Maria Nachury, Maud Reymond, et al.. (2022). Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clinical Gastroenterology and Hepatology. 21(9). 2338–2346.e3. 53 indexed citations

11.

Caprioli, Flavio, et al.. (2022). Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. BMC Health Services Research. 22(1). 1319–1319. 10 indexed citations

12.

Buisson, Anthony, Harry Sokol, Nassim Hammoudi, et al.. (2022). Role of adherent and invasive Escherichia coli in Crohn’s disease: lessons from the postoperative recurrence model. Gut. 72(1). 39–48. 33 indexed citations

13.

Singh, Siddharth, M. Hassan Murad, Mathurin Fuméry, Parambir S. Dulai, & William J. Sandborn. (2020). First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clinical Gastroenterology and Hepatology. 18(10). 2179–2191.e6. 232 indexed citations breakdown →

14.

Laharie, David, Stéphane Nancey, Xavier Hébuterne, et al.. (2020). Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease. Digestive and Liver Disease. 52(7). 740–744. 10 indexed citations

15.

Grados, Franck, et al.. (2020). Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life. Journal of Clinical Medicine. 9(10). 3319–3319. 7 indexed citations

16.

Bourrier, Anne, Maria Nachury, Stéphane Nancey, et al.. (2020). Vedolizumab for perianal Crohn’s disease: a multicentre cohort study in 151 patients. Alimentary Pharmacology & Therapeutics. 51(7). 719–727. 46 indexed citations

17.

Singh, Siddharth, Mathurin Fuméry, Abha G. Singh, et al.. (2019). Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis. Arthritis Care & Research. 72(4). 561–576. 112 indexed citations

18.

Auzolle, Claire, Stéphane Nancey, My‐Linh Tran‐Minh, et al.. (2018). Male gender, active smoking and previous intestinal resection are risk factors for post‐operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. Alimentary Pharmacology & Therapeutics. 48(9). 924–932. 63 indexed citations

19.

Foulon, Arthur, Jean‐Louis Dupas, Charles Sabbagh, et al.. (2017). Defining the Most Appropriate Delivery Mode in Women with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 23(5). 712–720. 53 indexed citations

20.

Fuméry, Mathurin, Benjamin Pariente, Hélène Sarter, et al.. (2016). Natural History of Crohnʼs Disease in Elderly Patients Diagnosed Over the Age of 70 Years. Inflammatory Bowel Diseases. 22(7). 1698–1707. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact